The arrival of J and J's vaccine is another sign.

It's going to be a glorious spring.

Think back a year ago and March was miserable as people realized the coronavirus pandemic was here to stay within days.

If you remember, Tom Hanks said, he was sick.

The NBA canceled its season, and the S and P 500 plunged by nearly a third.

It's been awhile, but this march will see this gloom finally start to lift as lots of people get vaccinated.

A.

J and J's vaccine is the third authorized the United States, and it has some advantages.

Unlike those made by Pfizer and Moderna, it's easy to store and ship, and it only requires one dose instead of to.

What really matters, though, is simply getting more shots into more arms.

So far, just over 50 million Americans are about 15% of total population has received at least one vaccine.

That number could double in March.

That's because fighters more than doubling capacity to 15 million doses a week, and Modern is raising production to 40 million months.

The addition of J and J adds another 20 million this month and 100 million by the end of Jim.

In short, vaccine production is accelerating fast, and that will eventually translate into fewer people getting sick and dying and less transmission of the disease.

That spring may be beautiful, but I'll probably be just as fitting for drugmaker's profit.

JJ's vaccine is priced at a fraction of the offerings from Madura Advisor, about $10 a shot, and more vaccines will probably be approved soon.

Sure, it will take a while to Rolla vaccines worldwide, but every new approval and production increase is a sign of a beautiful spring.